Supernus Pharmaceuticals SUPN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$2.29M+44.1% | -$4.11M+90.9% | -$45.12M-301% | $22.5M+290% | -$11.83M-177% | ||
| $26.13M+4.5% | $25.02M+0.8% | $24.81M+16.1% | $21.36M+4.8% | $20.38M+8.2% | ||
| $8.48M-12.1% | $9.65M+23.3% | $7.83M+4.2% | $7.51M-7.0% | $8.07M+5.7% | ||
| $5.92M-68.9% | $19M+818% | -$2.65M+63.1% | -$7.16M-79.5% | -$3.99M-5,442% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$5.62M-134% | $16.42M+130% | $7.13M+248% | -$4.81M-235% | $3.56M+207% | ||
| $105K-97.5% | $4.18M-67.7% | $12.94M+365% | -$4.89M-3.3% | -$4.73M-48.4% | ||
| $49K+110% | -$491K+97.7% | -$21.53M-232% | -$6.49M-265% | $3.94M+1,042% | ||
| $12.43M+80.0% | $6.91M-38.0% | $11.14M+345% | $2.5M+134% | -$7.37M-168% | ||
| -$284K— | —— | -$3.83M-15.9% | -$3.3M-594% | -$476K— | ||
| $21K— | —— | —— | —— | -$9K-500% | ||
| $2.26M— | —— | —— | —— | $1.34M-1.6% | ||
| $2.39M-86.5% | $17.76M— | $0— | $0-100% | $7.66M— | ||
| $66.52M+235% | $19.86M— | —— | $58.54M+91.3% | $30.6M-31.1% | ||
| $0-100% | $427K+231% | $129K-71.6% | $455K+39.1% | $327K+53.5% | ||
| $78.44M-13.0% | $90.2M-28.8% | $126.63M-9.9% | $140.56M+18.6% | $118.56M-18.5% | ||
| $59.22M+50.6% | $39.32M-91.6% | $468.56M+324% | $110.4M-29.3% | $156.2M+17.5% | ||
| -$19.22M— | —— | $48.71M— | —— | $37.32M+395% | ||
| $13.67M+59.8% | $8.56M-64.0% | $23.74M+625% | $3.28M+60.4% | $2.04M-70.3% | ||
| $4.56M+14,594% | $31K-96.2% | $811K+1,663% | $46K-98.6% | $3.34M+239% | ||
| $0— | $0-100% | $1.86M-18.9% | $2.3M-88.6% | $20.1M— | ||
| $9.12M+6.9% | $8.53M-59.5% | $21.07M+2,153% | $935K+104% | -$21.4M-463% | ||
| $56.42M— | —— | $8.11M-71.9% | $28.86M-38.0% | $46.52M— | ||
| -$412K-252% | $271K-91.2% | $3.08M-75.2% | $12.42M+4,434% | $274K-97.9% | ||
| $28.62M+223% | -$23.36M-759% | $3.54M-67.1% | $10.78M+655% | $1.43M— | ||
| $12.43M+80.0% | $6.91M-38.0% | $11.14M+345% | $2.5M+134% | -$7.37M-168% | ||
| $1.82M+160% | $698K— | —— | $920K+68.2% | $547K-92.1% | ||
| $192K— | —— | $921K+2,778% | $32K-97.0% | $1.07M— | ||
| $2.26M— | —— | —— | —— | $1.34M-1.6% | ||
| -$284K— | —— | -$3.83M-15.9% | -$3.3M-594% | -$476K— | ||
| $0— | —— | —— | —— | $4.9M— | ||
| $59.22M+50.6% | $39.32M-91.6% | $468.56M+324% | $110.4M-29.3% | $156.2M+17.5% | ||
| -$412K-252% | $271K-91.2% | $3.08M-75.2% | $12.42M+4,434% | $274K-97.9% | ||
| $66.52M+242% | $19.43M— | —— | $58.08M+91.9% | $30.27M-31.5% | ||
| $66.52M+242% | $19.43M— | —— | $58.08M+91.9% | $30.27M-31.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Supernus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.